The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myel...

Por Kraus, Johannes, Kraus, Marianne, Liu, Nora, Besse, Lenka, Bader, Jürgen, Geurink, Paul P., de Bruin, Gerjan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Publicado no Cancer Chemother Pharmacol (2015)

Autophagy promotes MHC class II presentation of peptides from intracellular source proteins

Por Dengjel, Jörn, Schoor, Oliver, Fischer, Rainer, Reich, Michael, Kraus, Marianne, Müller, Margret, Kreymborg, Katharina, Altenberend, Florian, Brandenburg, Jens, Kalbacher, Hubert, Brock, Roland, Driessen, Christoph, Rammensee, Hans-Georg, Stevanovic, Stefan
Publicado em 2005

HIV-1–infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase

Por Harman, Andrew N., Kraus, Marianne, Bye, Chris R., Byth, Karen, Turville, Stuart G., Tang, Owen, Mercier, Sarah K., Nasr, Najla, Stern, Josh L., Slobedman, Barry, Driessen, Christoph, Cunningham, Anthony L.
Publicado em 2009

Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

Por Auner, Holger W., Moody, Anne Marie, Ward, Theresa H., Kraus, Marianne, Milan, Enrico, May, Philippa, Chaidos, Aristeidis, Driessen, Christoph, Cenci, Simone, Dazzi, Francesco, Rahemtulla, Amin, Apperley, Jane F., Karadimitris, Anastasios, Dillon, Niall
Publicado em 2013

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with...

Por Driessen, Christoph, Kraus, Marianne, Joerger, Markus, Rosing, Hilde, Bader, Jürgen, Hitz, Felicitas, Berset, Catherine, Xyrafas, Alexandros, Hawle, Hanne, Berthod, Gregoire, Overkleeft, Hermann S., Sessa, Christiana, Huitema, Alwin, Pabst, Thomas, von Moos, Roger, Hess, Dagmar, Mey, Ulrich J.M.
Publicado no Haematologica (2016)

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Por Kraus, Marianne, Bader, Juergen, Geurink, Paul P., Weyburne, Emily S., Mirabella, Anne C., Silzle, Tobias, Shabaneh, Tamer B., van der Linden, Wouter A., de Bruin, Gerjan, Haile, Sarah R., van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Publicado no Haematologica (2015)